It appears as though Bill Freytag, Ph.D. former chief executive of Myogen will be assuming the CEO and chair positions with Aspreva Pharmaceuticals (NASDAQ: ASPV) effective immediately. Aspreva, based in Victoria, British Columbia has two Phase III trials underway for the autoimmune diseases lupus nephritis and pemphigus vulgaris.
More news to come…
No comments:
Post a Comment